ImageneBio files prospectus supplement for 2,508,337-share resale

Rhea-AI Filing Summary

ImageneBio, Inc. filed a prospectus supplement covering the proposed offer and resale, from time to time, by selling stockholders of 2,508,337 shares of common stock.

The supplement updates the base prospectus by attaching the company’s Quarterly Report on Form 10-Q filed on November 12, 2025. ImageneBio’s common stock trades on the Nasdaq Capital Market under the ticker IMA; the last reported sales price was $8.61 per share on November 11, 2025. The filing reiterates that investing in the securities involves a high degree of risk, directing readers to the Risk Factors in the prospectus.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/12/2025 - 08:45 AM Learn about SEC filing dates

FAQ

What is ImageneBio (IMA) registering in this prospectus supplement?

The supplement relates to the proposed offer and resale, from time to time, by selling stockholders of 2,508,337 shares of common stock.

Who may sell the shares covered by this filing?

The selling stockholders identified in the Prospectus may offer and resell the shares from time to time.

What does this prospectus supplement add to the base prospectus?

It updates the prospectus by attaching ImageneBio’s Quarterly Report on Form 10-Q filed on November 12, 2025.

Where is ImageneBio’s common stock listed and under what symbol?

It is listed on the Nasdaq Capital Market under the ticker IMA.

What was the last reported price for IMA common stock?

The last reported sales price was $8.61 per share on November 11, 2025.

Under what rule was this prospectus supplement filed?

It was filed pursuant to Rule 424(b)(3).

Filed Pursuant to Rule 424(b)(3)
Registration No. 333-290108

PROSPECTUS SUPPLEMENT

(To the Prospectus dated September 15, 2025)

ImageneBio, Inc.

2,508,337 Shares of Common Stock

This prospectus supplement supplements the prospectus, dated September 15, 2025 (the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 333-290108). This prospectus supplement is being filed to update and supplement the information in the Prospectus with certain information contained in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 12, 2025 (the “Quarterly Report”). Accordingly, we have attached the Quarterly Report to this prospectus supplement.

The Prospectus and this prospectus supplement relate to the proposed offer and resale or other disposition from time to time by the selling stockholders identified in the Prospectus of 2,508,337 shares of common stock, par value $0.001 per share (“Common Stock”), of ImageneBio, Inc.

Our Common Stock is listed on the Nasdaq Capital Market under the ticker symbol “IMA.” On November 11, 2025, the last reported sales price of our Common Stock was $8.61 per share.

This prospectus supplement should be read in conjunction with the Prospectus, including any amendments or supplements thereto, which is to be delivered with this prospectus supplement. This prospectus supplement is qualified by reference to the Prospectus, including any amendments or supplements thereto, except to the extent that the information in this prospectus supplement updates and supersedes the information contained therein.

This prospectus supplement is not complete without, and may not be delivered or utilized except in connection with, the Prospectus, including any amendments or supplements thereto.

Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described in the section titled “Risk Factors” beginning on page 6 of the Prospectus and under similar headings in any amendments or supplements to the Prospectus.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities, or passed upon the accuracy or adequacy of this prospectus supplement or the Prospectus. Any representation to the contrary is a criminal offense.

The date of this prospectus supplement is November 12, 2025